SS-20

SS-20 (SBT-20; H-Phe-D-Arg-Phe-Lys-NH2; CAS 736992-19-1; molecular weight 595.75; molecular formula C30H45N9O4) is a cell-permeable, mitochondria-targeted synthetic tetrapeptide of the Szeto-Schiller (SS) class, developed at the Department of Pharmacology at Weill Cornell Medical College by Hazel H. Szeto and colleagues as a structural analog of SS-31 (elamipretide) that retains mitochondrial targeting and cardiolipin binding but lacks the 2',6'-dimethyltyrosine (Dmt) residue responsible for intrinsic reactive oxygen species scavenging in SS-31 [1, 2]. The deliberate substitution of phenylalanine for Dmt at position 1 eliminates the phenolic hydroxyl group that confers direct radical-scavenging capacity, making SS-20 an indispensable mechanistic control compound that has proven essential for establishing that cardiolipin interaction, rather than antioxidant chemistry, is the operative therapeutic mechanism of the SS peptide class [3, 4]. SS-20 carries a net 3+ charge at physiological pH and concentrates approximately 1000-fold on the inner mitochondrial membrane (IMM), where it binds the tetra-acyl dianion cardiolipin through electrostatic interactions between its basic residues (D-Arg, Lys) and the cardiolipin phosphate head groups, with its aromatic phenylalanine residues inserting into the hydrophobic acyl chain region [5, 6]. This binding modulates the interaction between cardiolipin and cytochrome c, promoting the electron carrier function of cytochrome c over its peroxidase activity, thereby improving mitochondrial electron transport chain coupling efficiency, increasing ATP synthesis per unit oxygen consumed, and reducing mitochondrial reactive oxygen species generation as a downstream consequence of improved coupling rather than through direct scavenging [3, 4]. In preclinical models, SS-20 has demonstrated efficacy comparable to SS-31 in protecting against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mice at 4 mg/kg intraperitoneal, with complete preservation of tyrosine hydroxylase-immunoreactive neurons in the substantia nigra pars compacta and 40 percent attenuation of striatal dopamine depletion [7]. In renal ischemia-reperfusion models, pretreatment with SS-20 extended warm ischemia tolerance in rat kidneys from 30 to 45 minutes, preserved cristae architecture on electron microscopy, restored tissue ATP levels, and reduced apoptosis, cytoskeletal breakdown, and interstitial fibrosis [8]. In cardiac ischemia-reperfusion, intravenous SS-20 (SBT-20) at 0.3 and 3.0 mg/kg/hour reduced myocardial infarct size by 20 percent relative to saline control in a rat coronary occlusion model, outperforming the reported 11 percent reduction achieved by elamipretide (MTP-131) in comparable protocols [9]. In pressure-overload heart failure induced by transverse aortic constriction (TAC) in mice, SS-20 produced partial but significant attenuation of cardiac hypertrophy and improvement in fractional shortening, with preferential protection of actin cytoskeletal pathways over mitochondrial and metabolic pathways in global proteomic analysis, a pattern distinct from the broader mitochondrial proteomic protection provided by SS-31 [10]. In chronic renal failure induced by 5/6 nephrectomy in mice, SBT-20 at 5 mg/kg intraperitoneal reduced inflammatory cytokines (interleukin-1-beta, interleukin-6, tumor necrosis factor alpha), normalized NF-kappaB signaling, restored mitochondrial membrane potential, and improved serum creatinine, blood urea nitrogen, and creatinine clearance [11]. The compound has not entered human clinical trials; all pharmacological characterization is preclinical. SS-20 is not approved by any regulatory authority for any indication. It is supplied as a research-grade synthetic peptide by multiple chemical suppliers at greater than 98 percent purity by high-performance liquid chromatography and is used principally as a mechanistic tool to dissect the relative contributions of cardiolipin binding and antioxidant activity within the SS peptide class, and as a candidate therapeutic lead for ischemia-reperfusion injury, neurodegenerative disease, and chronic kidney disease in settings where direct radical scavenging may not be the desired pharmacological intervention.